2022年6月5日,NEJM Evidence期刊上刊登了《Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma》,度伐利尤单抗联合曲美木单抗(D+T)治疗不可切除的肝细胞癌的研究结果。追踪各种会议和期刊上的研究数据的更新,本身就是一件辛苦的事情,但不追踪,看到自己制作的幻灯,老是讲以前的数据,如鲠在喉的感觉...
However, there is a theoretical risk of graft rejection with immunostimulatory treatment.Methods:This is a single-arm, open-label, Phase II, multicenter study designed to evaluate the safety and efficacy of durvalumab and tremelimumab for the treatment of HCC patients who have cirrhosis or portal ...
Die Zulassung von Durvalumab als Monotherapie und in Kombination mit Tremelimumab basiere auf der dreiarmi gen Phase-III-Studie HIMALAYA mit 1.171 Erwachsenen [Abou-Alfa NEJM Evid. 2022;1(8):EVIDoa2100070], berich tete Florian van Bömmel, Leipzig. Die Durvalumab-Monotherapie war ...
In the global, Phase 3 HIMALAYA study (NCT03298451) in uHCC, the STRIDE regimen (Single T Regular Interval D) significantly improved overall survival vs sorafenib (S); D monotherapy was noninferior to S (Abou-Alfa et al. NEJM Evid 2022). Here, we analyzed ADAs to T and D in HIMALAYA...